BDNF (Brain-Derived Neurotrophic Factor): Definition and Role in Ketamine Therapy

Definition

Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family of growth factors. It is primarily produced in the brain and plays a critical role in the survival, growth, and maintenance of neurons. BDNF supports synaptic plasticity — the ability of synapses to strengthen or weaken over time — and is essential for learning, memory formation, and the overall health of neural circuits.

BDNF is one of the most studied molecules in modern neuroscience, and its relevance to ketamine therapy is central. The rapid increase in BDNF expression following ketamine administration is believed to be a key mediator of ketamine's antidepressant and neuroplastic effects.

How BDNF Works

Synthesis and Release

BDNF is synthesized as a precursor protein (proBDNF) and is converted to its mature form through enzymatic cleavage. It is produced by neurons throughout the brain, with particularly high concentrations in the hippocampus, prefrontal cortex, and amygdala — regions critically involved in mood regulation, memory, and emotional processing.

Mature BDNF is released from neurons in an activity-dependent manner, meaning that its secretion increases when neurons are actively firing. Once released, BDNF binds to its primary receptor, tropomyosin receptor kinase B (TrkB), on the surface of nearby neurons. This binding activates intracellular signaling cascades that promote neuronal survival, synaptic strengthening, and the growth of new dendritic spines.

Downstream Signaling

When BDNF activates the TrkB receptor, it triggers several important molecular pathways:

• The MAPK/ERK pathway — Promotes cell survival and differentiation
• The PI3K/Akt pathway — Supports neuronal survival and growth
• The PLCgamma pathway — Modulates synaptic plasticity and calcium signaling
• The mTOR pathway — Stimulates protein synthesis necessary for new synapse formation

The mTOR (mechanistic target of rapamycin) pathway is particularly relevant to ketamine's mechanism, as it directly drives the synthesis of synaptic proteins needed for the rapid formation of new connections.

BDNF and Depression

The Neurotrophic Hypothesis

The neurotrophic hypothesis of depression proposes that depression is associated with reduced BDNF levels and impaired neuroplasticity, particularly in the hippocampus and prefrontal cortex. This theory is supported by multiple lines of evidence:

• Post-mortem studies have found reduced BDNF levels in the brains of individuals who died by suicide or had a history of depression
• Blood serum BDNF levels are lower in patients with depression compared to healthy controls
• Chronic stress — a major risk factor for depression — decreases BDNF expression in animal models
• Successful antidepressant treatment (including SSRIs, exercise, and electroconvulsive therapy) is associated with increased BDNF levels

The reduction in BDNF contributes to synaptic atrophy — the loss of synaptic connections — in brain regions critical to mood regulation. This structural deterioration is thought to underlie many of the cognitive and emotional symptoms of depression.

BDNF as a Biomarker

Serum BDNF levels have been investigated as a potential biomarker for depression severity and treatment response. While not yet used clinically for diagnostic purposes, research consistently shows that BDNF levels tend to normalize with effective treatment and that baseline BDNF levels may predict response to certain therapies.

BDNF and Ketamine's Mechanism of Action

Rapid BDNF Upregulation

One of ketamine's most distinctive properties is its ability to rapidly increase BDNF levels within hours of administration — far faster than conventional antidepressants, which may take weeks to produce similar neurotrophic effects. This rapid BDNF release is believed to be a direct consequence of the glutamate surge triggered by NMDA receptor blockade.

The proposed sequence is:

1. Ketamine blocks NMDA receptors on GABAergic interneurons
2. Reduced inhibition leads to increased glutamate release
3. Excess glutamate activates AMPA receptors
4. AMPA activation triggers BDNF release from neurons
5. BDNF binds to TrkB receptors and activates the mTOR pathway
6. mTOR activation drives rapid synthesis of synaptic proteins
7. New synaptic connections form within hours (synaptogenesis)

This cascade explains how ketamine can produce structural changes in neural circuits within a timeframe of hours, whereas traditional antidepressants require weeks of continuous administration to achieve comparable neuroplastic effects.

Evidence From Preclinical Studies

Animal studies have provided compelling evidence for BDNF's role in ketamine's mechanism:

• Ketamine's antidepressant-like effects in rodents are abolished when BDNF signaling is genetically blocked
• Mice with a BDNF gene variant (Val66Met) that impairs BDNF release show reduced response to ketamine
• Direct infusion of BDNF into the prefrontal cortex of rodents produces antidepressant-like effects similar to those of ketamine

Clinical Relevance

In human studies, patients who respond to ketamine treatment show greater increases in serum BDNF levels compared to non-responders. The Val66Met polymorphism in the human BDNF gene — carried by approximately 20-30% of the population — has been associated with altered response to ketamine, though findings have been inconsistent across studies. This genetic variation may eventually help identify which patients are most likely to benefit from ketamine therapy.

Key Takeaways

• BDNF is a growth factor essential for neuronal survival, synaptic plasticity, and brain health
• Reduced BDNF levels are associated with depression and other psychiatric conditions
• Ketamine rapidly increases BDNF expression, triggering a cascade that promotes the formation of new synaptic connections
• The BDNF-mediated synaptogenic effect is considered a primary mechanism underlying ketamine's rapid antidepressant action. For an in-depth look at BDNF signaling pathways, see our partner research resources
• BDNF levels may serve as a future biomarker for predicting and monitoring treatment response

References

• Ketamine's Mechanism of Action: A Path to Rapid-Acting Antidepressants — NIH review detailing the role of BDNF in ketamine's antidepressant cascade
• StatPearls: Ketamine — Clinical reference covering ketamine's neurotrophic effects and BDNF upregulation
• NIMH: Depression — National Institute of Mental Health information on the neurotrophic hypothesis of depression